Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q1 2020 Earnings Presentation
8 slides from Anika Therapeutics's earnings presentation, May 7, 2020
Slide 1: First Quarter 2020 Earnings Call Presentation
FIRST QUARTER 2020 EARNINGS CALL PRESENTATION MAY 7, 2020 Nasdaq: ANIK
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Our Response to COVID-19 Pandemic
OUR RESPONSE TO COVID-19 PANDEMIC • Taking necessary steps to protect the health and well-being of our employees, patients we serve, and our communities • Strengthening liquidity to navigate uncertainty of the COVID-19 pandemic and beyond • Implementing short-term expense controls; Prioritizing key
Slide 4: Clinical Trials Update
CLINICAL TRIALS UPDATE CINGAL Pilot Study • Fully engaging all stakeholders in the clinical trial ecosystem • Pre-enrollment activities are substantially complete • No longer expect to begin the CINGAL pilot study in the 1H 2020 due to COVID-19 pandemic; Plan to initiate the study as soon as safely
Slide 5: Arthrosurface and Parcus Medical Integration Update
ARTHROSURFACE AND PARCUS MEDICAL INTEGRATION UPDATE • Held first national sales meeting in February, following completion of the Arthrosurface and Parcus Medical acquisitions • Combined team is armed with a common vision, well-defined goals, necessary tools, and the roadmap to achieve them • During
Slide 6: Anika Product Families
ANIKA PRODUCT FAMILIES Product Family Subcategories Key Products Joint Pain • Human viscosupplements • MONOVISC, CINGAL, ORTHOVISC Management • Veterinary viscosupplements • HYVISC • Soft-tissue implants and instrumentation, and • Parcus Medical & Arthrosurface Orthopedic Joint partial and extremiti
Slide 7: Q1 2020 Financial Highlights
(1) Q1 2020 FINANCIAL HIGHLIGHTS Dollars in millions, except EPS (1),(2) Total Revenue Adjusted EBITDA Q1 2020(1) Q1 2020 (2) $35.4 $9.5 U.S. GAAP Non-GAAP $8.3 $24.7 Net Income $3.5M $6.5M Diluted EPS $0.24 $0.45 Q1 2019 Q1 2020 Q1 2019 Q1 2020 • Record Q1 total revenue despite end of quarter COVID
Slide 8: First Quarter 2020 Earnings Call Presentation
FIRST QUARTER 2020 EARNINGS CALL PRESENTATION MAY 7, 2020 Nasdaq: ANIK